Bladder Cancer

Ongoing Clinical Trials

Trial Status

Protocol Number: SPI-612 03/2009 - Present
Sponsor: Spectrum Pharmaceuticals
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical EOquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer.

Purpose of Study
The purpose of this study is to evaluate the recurrence rate of bladder cancer at two years in patients with low grade bladder tumors, who have undergone Transurethral Resection of bladder tumor (TUR-BT) plus EOquin® versus those who receive TUR-BT plus placebo. This study will enroll adult patients with noninvasive bladder cancer.

For further information, click here.

List of Completed Trials for Bladder Cancer

Protocol Number: TRI-00-0001 02/2000 – 01/2007  
Sponsor: Schering Plough

Title: A multicenter trial of induction and six courses of three week maintenance with BCG versus BCG plus Interferon Alfa-2B in the treatment of superficial bladder cancer.

Clinical Research Coordinators:
Lisa Bennett, RN or Michelle Utrera (336) 274-1114 ext. 5322
E-mail address:

Website Graphics by Vintage Marketing